Cancer Center Karolinska, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Cancer Center Karolinska, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Int Rev Cell Mol Biol. 2018;339:1-40. doi: 10.1016/bs.ircmb.2018.02.006. Epub 2018 Apr 3.
Receptor tyrosine kinases (RTKs) such as the insulin-like growth factor type 1 receptor (IGF-1R) control important biological activities as well as being involved in pathological processes. Due to their supportive nature in many human cancers they have long been considered attractive therapeutic targets. However, lessons learnt from early targeting trials highlight that a simple "active versus inactive" state model with classical kinase-only signaling is overly simplistic and does not describe reality. A vast amount of evidence exists disproving this model and hence provides a rational explanation for failure of many targeting agents designed under such a paradigm. In addition, substantial evidence exists that the IGF-1R and other RTKs make direct use of the G protein-coupled receptor (GPCR) components G proteins, GRKs, and β-arrestins, outside of their traditional receptor family frame. In this chapter we review the evidence that RTKs can undertake a wide range of active conformations, capable of distinct downstream signal cascades and propose an RTK/GPCR functional hybrid model, while discussing the implications of such an update on therapeutic drug development pipelines.
受体酪氨酸激酶(RTKs),如胰岛素样生长因子 1 型受体(IGF-1R),控制着重要的生物学活性,并参与病理过程。由于它们在许多人类癌症中的支持性质,它们长期以来一直被认为是有吸引力的治疗靶点。然而,从早期靶向试验中吸取的教训强调,一个简单的“激活与失活”状态模型,带有经典的激酶信号,过于简单化,不能描述现实。大量证据表明这种模型是错误的,因此为许多在这种模式下设计的靶向药物的失败提供了合理的解释。此外,大量证据表明,IGF-1R 和其他 RTKs 在其传统受体家族框架之外,直接利用 G 蛋白偶联受体(GPCR)成分 G 蛋白、GRK 和β-arrestin,进行广泛的活性构象,能够进行不同的下游信号级联反应,并提出了 RTK/GPCR 功能混合模型,同时讨论了这种更新对治疗药物开发管道的影响。